Sundry Photography/iStock Editorial via Getty Images
- Abbott Laboratories (NYSE:ABT) on Thursday announced the market launch of Lingo, its first continuous glucose monitoring system available without a prescription.
- The North Chicago, Illinois-based MedTech giant said that Lingo is available for people aged 18 and above who are not on insulin.
- Abbott (ABT) and its rival in the glucose monitoring space, DexCom (DXCM), won FDA clearances for their over-the-counter CGM devices in June ahead of their planned market rollouts this summer.
- Last week, DexCom (DXCM) launched its product, Stelo, at $99 for a single pack of two sensors. Abbott (ABT) has priced its device at $89 for two sensors.
- “Abbott’s Lingo tracks your glucose 24/7, translating the data into insights and bridging the gap between traditional healthcare and preventative measures,” said Olivier Ropars, Abbott’s divisional vice president of Lingo.
